148 related articles for article (PubMed ID: 3385360)
1. Complement activation is required for IgM-mediated enhancement of the antibody response.
Heyman B; Pilström L; Shulman MJ
J Exp Med; 1988 Jun; 167(6):1999-2004. PubMed ID: 3385360
[TBL] [Abstract][Full Text] [Related]
2. The failure to show a necessary role for C3 in the in vitro antibody response.
Waldmann H; Lachmann PJ
Eur J Immunol; 1975 Mar; 5(3):185-93. PubMed ID: 1086224
[TBL] [Abstract][Full Text] [Related]
3. Antigen-dependent IgM-mediated enhancement of the sheep erythrocyte response in mice. Evidence for induction of B cells with specificities other than that of the injected antibodies.
Heyman B; Andrighetto G; Wigzell H
J Exp Med; 1982 Apr; 155(4):994-1009. PubMed ID: 6174678
[TBL] [Abstract][Full Text] [Related]
4. In Contrast to Anti-C5 Therapy, Cobra Venom Factor Does Not Prevent Rejection of Xenogeneic Cartilage in Mice.
Brokaw JL; Costa C
Transplant Proc; 2015 Oct; 47(8):2397-9. PubMed ID: 26518939
[TBL] [Abstract][Full Text] [Related]
5. Complement-activating IgM enhances the humoral but not the T cell immune response in mice.
Ding Z; Bergman A; Rutemark C; Ouchida R; Ohno H; Wang JY; Heyman B
PLoS One; 2013; 8(11):e81299. PubMed ID: 24250831
[TBL] [Abstract][Full Text] [Related]
6. Absence of a neutralizing antibody response to humanized cobra venom factor in mice.
Ing M; Hew BE; Fritzinger DC; Delignat S; Lacroix-Desmazes S; Vogel CW; Rayes J
Mol Immunol; 2018 May; 97():1-7. PubMed ID: 29525557
[TBL] [Abstract][Full Text] [Related]
7. Endogenous complement-activating IgM is not required for primary antibody responses but promotes plasma cell differentiation and secondary antibody responses to a large particulate antigen in mice.
Palm AE; Westin A; Ayranci D; Heyman B
Front Immunol; 2023; 14():1323969. PubMed ID: 38259486
[TBL] [Abstract][Full Text] [Related]
8. Impaired humoral immune response in complement C3-deficient guinea pigs: absence of secondary antibody response.
Böttger EC; Metzger S; Bitter-Suermann D; Stevenson G; Kleindienst S; Burger R
Eur J Immunol; 1986 Oct; 16(10):1231-5. PubMed ID: 2945728
[TBL] [Abstract][Full Text] [Related]
9. Role of antibody synthesis and complement activation in concordant xenograft retransplantation.
Gannedahl G; Karlsson-Parra A; Wallgren A; Roos-Engstrand E; Nilsson B; Tötterman TH; Tufveson G
Transplantation; 1994 Aug; 58(3):337-44. PubMed ID: 8053058
[TBL] [Abstract][Full Text] [Related]
10. Cobra venom factor immunoconjugates: effects of carbohydrate-directed versus amino group-directed conjugation.
Zara J; Pomato N; McCabe RP; Bredehorst R; Vogel CW
Bioconjug Chem; 1995; 6(4):367-72. PubMed ID: 7578355
[TBL] [Abstract][Full Text] [Related]
11. A Novel Mechanism for Generating the Interferon Signature in Lupus: Opsonization of Dead Cells by Complement and IgM.
Zhuang H; Han S; Li Y; Kienhöfer D; Lee P; Shumyak S; Meyerholz R; Rosadzinski K; Rosner D; Chan A; Xu Y; Segal M; Sobel E; Yang LJ; Hoffmann MH; Reeves WH
Arthritis Rheumatol; 2016 Dec; 68(12):2917-2928. PubMed ID: 27274010
[TBL] [Abstract][Full Text] [Related]
12. Studies on immunosuppression by cobra venom factor. III. On early responses to sheep erythrocytes in C5-deficient mice.
Martinelli GP; Matsuda T; Waks HS; Osler AG
J Immunol; 1978 Nov; 121(5):2052-5. PubMed ID: 712078
[TBL] [Abstract][Full Text] [Related]
13. Depletion of complement has distinct effects on the primary and secondary antibody responses to a conjugate of pneumococcal serotype 14 capsular polysaccharide and a T-cell-dependent protein carrier.
Test ST; Mitsuyoshi JK; Hu Y
Infect Immun; 2005 Jan; 73(1):277-86. PubMed ID: 15618164
[TBL] [Abstract][Full Text] [Related]
14. Evidence of IgG-mediated enhancement of the antibody response in vivo without complement activation via the classical pathway.
Wiersma EJ; Nose M; Heyman B
Eur J Immunol; 1990 Dec; 20(12):2585-9. PubMed ID: 2269326
[TBL] [Abstract][Full Text] [Related]
15. Additive cytotoxicity of different monoclonal antibody-cobra venom factor conjugates for human neuroblastoma cells.
Juhl H; Petrella EC; Cheung NK; Bredehorst R; Vogel CW
Immunobiology; 1997 Nov; 197(5):444-59. PubMed ID: 9413745
[TBL] [Abstract][Full Text] [Related]
16. Complement and myoblast transfer therapy: donor myoblast survival is enhanced following depletion of host complement C3 using cobra venom factor, but not in the absence of C5.
Hodgetts SI; Grounds MD
Immunol Cell Biol; 2001 Jun; 79(3):231-9. PubMed ID: 11380675
[TBL] [Abstract][Full Text] [Related]
17. IgG Suppresses Antibody Responses in Mice Lacking C1q, C3, Complement Receptors 1 and 2, or IgG Fc-Receptors.
Bergström JJ; Heyman B
PLoS One; 2015; 10(11):e0143841. PubMed ID: 26619292
[TBL] [Abstract][Full Text] [Related]
18. Antibody-mediated modulation of the immune response.
Reiter J; Hutchings P; Lydyard PM; Cooke A
Cell Immunol; 1986 Jan; 97(1):91-101. PubMed ID: 3488826
[TBL] [Abstract][Full Text] [Related]
19. Recombinant cobra venom factor.
Vogel CW; Fritzinger DC; Hew BE; Thorne M; Bammert H
Mol Immunol; 2004 Jun; 41(2-3):191-9. PubMed ID: 15159065
[TBL] [Abstract][Full Text] [Related]
20. The failure to show a necessary role for C3 in the in vitro antibody response.
Waldmann H; Lachmann PJ
Eur J Immunol; 1975 Feb; 5(2):185-93. PubMed ID: 1086222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
